Raj Shah to Cardiovascular Diseases
This is a "connection" page, showing publications Raj Shah has written about Cardiovascular Diseases.
Connection Strength
1.636
-
Aligning the 4Ms of Age-Friendly Health Systems With Statin Use for Primary Prevention. J Am Geriatr Soc. 2020 03; 68(3):463-464.
Score: 0.513
-
Prediabetes, diabetes and loss of disability-free survival in a community-based older cohort: a post-hoc analysis of the ASPirin in Reducing Events in the Elderly trial. Age Ageing. 2023 04 01; 52(4).
Score: 0.160
-
Cognitive trajectories and incident dementia after a cardiovascular event in older adults. Alzheimers Dement. 2023 08; 19(8):3670-3678.
Score: 0.159
-
Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. Am J Kidney Dis. 2022 12; 80(6):810-813.
Score: 0.150
-
Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial. Ann Intern Med. 2022 05; 175(5):761-764.
Score: 0.149
-
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021 02; 99(2):466-474.
Score: 0.134
-
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018 10 18; 379(16):1509-1518.
Score: 0.117
-
The aspirin in reducing events in the elderly trial: Statistical analysis plan. Int J Stroke. 2018 04; 13(3):335-338.
Score: 0.110
-
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci. 2017 Oct 12; 72(11):1586-1593.
Score: 0.109
-
Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. J Am Geriatr Soc. 2021 12; 69(12):3568-3575.
Score: 0.036